



## Otovel<sup>®</sup> (ciprofloxacin/fluocinolone) – First-time authorized brand alternative (ABA)

- On October 30, 2019, Wilshire Pharmaceuticals launched an authorized brand alternative of Laboratorios Salvat/Arbor's [Otovel \(ciprofloxacin/fluocinolone\)](#) otic solution.
- Otovel is approved for the treatment of acute otitis media with tympanostomy tubes in pediatric patients (aged 6 months and older) due to *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Moraxella catarrhalis*, and *Pseudomonas aeruginosa*.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.